That's huge progress in a short time. When sheâs not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Returns as of 02/25/2021. The high price target for VXRT is $22.00 and the low price target for VXRT is $17.00. © American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved. VXRT's SEC filings can be seen here. The stock has a market cap of $990.69 million, a PE ratio of -15.34 and a beta of -0.11. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Midway through trading Wednesday, the Dow traded down 0.04% to 30,674.36 while the NASDAQ rose 0.25% to 13,646.18. In November, the company said it had completed enrollment. But its vaccine doesn't involve a jab; it's a tablet to be taken orally. 2 Wall Street analysts have issued ratings and price targets for Vaxart in the last 12 months. Vaxart is a biotech company that is looking to develop a unique Covid-19 vaccine that can be administered via tablets, eliminating the need for a needle-based injection. So cautious investors are better off watching this stock market mover from the sidelines. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Learn everything you need to know about successful options trading with this three-part video course. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Vaxart launched the phase 1 trial of its vaccine candidate in October. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Are you looking for the next great pet stock play? Shares rose as the company announced its development of the vaccine and investors hoped it might be included in a list of vaccine developers to receive government funding. Fundamental company data provided by Zacks Investment Research. Learn about financial terms, types of investments, trading strategies and more. The high price target for VXRT is $22.00 and the low price target for VXRT is $17.00. ⦠MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. In recent trading, shares of Vaxart Inc (Symbol: VXRT) have crossed above the average analyst 12-month target price of $17.67, changing hands for $23.33/share⦠So any good news ahead can easily send the share price higher. The figure suggests upside potential of 79% in the year ahead. Their average twelve-month price target is $19.50, predicting that the stock has a possible upside of 165.67%. Cumulative Growth of a $10,000 Investment in Stock Advisor, Did You Miss Out on a 2,000% Gain with Vaxart Stock? But letâs not forget⦠it wasnât so long ago that cryptos were dropping by 90% (or more) in just a few weeks time... New pre-clinical histology data show that Vaxartâs oral vaccine protected against lung inflammation in hamster models. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Like more than 50 other companies, Vaxart is developing a potential coronavirus vaccine. The chart below shows how a company's share price and consensus price target have changed over time. And it could most certainly happen again. Identify stocks that meet your criteria using seven unique stock screeners. Vaxart's market value has climbed from about $16 million at the start of the year to more than $800 million. Don't miss this opportunity as FRPT is already trading over 100 dollars per share!document.write(''); View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. But the company has advanced its vaccine candidate into human trials. Vaxart, Inc (US:VXRT) has 270 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). 02/20 Is bitcoin headed to $100,000 in 2021 or is its price ... Royalty Pharma increases quarterly dividend by 13% to 17 cents a share. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. See what's happening in the market right now with MarketBeat's real-time news feed. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. But don't chase Vaxart gains unless you're an aggressive investor. Adria Cimino grew up with her nose in a book and a love of storytelling. Vaxart has a 1 year low of $1.00 and a 1 year high of $24.90. Vaxart launched the phase 1 trial of its vaccine candidate in October. Vaxart Company Profile And we do expect news in the near future. Please log in to your account or sign up in order to add this asset to your watchlist. View our full suite of financial calendars and market data tables, all for free. @themotleyfool #stocks $VXRT, Better Coronavirus Stock: Inovio Pharmaceuticals vs. Vaxart, Copyright, Trademark and Patent Information. The lighter blue line represents the stock's consensus price target. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The dark blue line represents the company's actual price. Whether youâre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. O ver the past week, investors optimistically pushed Vaxartâs share price up by over 100%.High short-interest and anticipation of positive Phase 1 results from the ⦠If the upcoming results are positive, I would expect further share gains. Investors have awarded Vaxart (NASDAQ:VXRT) for its innovation this year. You may have missed out on Vaxart's 2,105% gain this year if you didn't invest in the shares in the first quarter. Today, you can download 7 Best Stocks for the Next 30 Days. Want the latest recommendations from Zacks Investment Research? And if Vaxart's program makes it to regulatory authorization, the stock could skyrocket. You can opt out at any time. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Do Not Sell My Information. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months.
Blueberry Yeast Bread, Postmates Taxes And Fees, Audie Murphy War Movies, Paley Center For Media Archives, Fbc 2020 Effective Date, House Wine Box Review, Psalm 148 Nrsv, Mecha Sonic 3, Estufa Koblenz Empotrable, Gloss Shampoo And Conditioner, Rx7 Fd For Sale,